Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.64 |
| ▸ | BRD4 | O60885 | 5/20 | 0.55 |
| ▸ | DRD2 | P14416 | 3/20 | 0.54 |
| ▸ | DRD4 | P21917 | 3/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | SPR | P35270 | 1/20 | 0.45 |
| ▸ | AKT1 | P31749 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7993369 | 0.87 | DRD2 (0.54) | NOTUMDRD2DRD4PKMALDH1A1 | |
| SCHEMBL7593171 | 0.85 | NOTUM (0.57) | NOTUMBRD4DRD2DRD4PKM | |
| SCHEMBL14895362 | 0.84 | NOTUM (0.60) | NOTUMBRD4PKMALDH1A1NPC1 | |
| SCHEMBL18701883 | 0.83 | DRD2 (0.51) | NOTUMDRD2DRD4PKMSPR | |
| SCHEMBL24347712 | 0.80 | NOTUM (0.59) | NOTUMBRD4PKMALDH1A1NPC1 | |
| SCHEMBL21172780 | 0.80 | NOTUM (0.59) | NOTUMBRD4PKMALDH1A1NPC1 | |
| SCHEMBL21172449 | 0.80 | NOTUM (0.63) | NOTUMBRD4DRD2DRD4PKM | |
| SCHEMBL22842630 | 0.79 | SPR (0.49) | NOTUMDRD2DRD4PKMSPR | |
| SCHEMBL10167044 | 0.78 | NOTUM (1.00) | NOTUMPKMSPRALDH1A1NPC1 | |
| SCHEMBL2586534 | 0.78 | NOTUM (1.00) | NOTUMPKMSPRALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-04-06 | — | — | US | disclosed |
| EP-0656003-A1 | CONDENSED INDOLE DERIVATIVES AS 5HT2C AND 5HT2B ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | SPR, QDPR, SRR | NOTUM 2116/4885BRD4 4039/4885DRD2 1811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.